Exane Asset Management Adverum Biotechnologies, Inc. Transaction History

Exane Asset Management

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 05, 2019	SELL	$2.87 - $5.92 $195,160 - $402,560	-68,000 Closed	0 $0
Q3 2018 Nov 16, 2018	BUY	$4.5 - $7.6 $81,000 - $136,800	18,000 Added 36.0%	68,000 $0
Q2 2018 Sep 06, 2018	BUY	$5.3 - $6.9 $265,000 - $345,000	50,000 New	50,000 $0

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $680M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

Stay updated on Exane Asset Management with notifications on news.